Agios Pharmaceuticals, Inc. 宣布，美国食品药品监督管理局（FDA）已接受其药物Mitapivat用于治疗镰状细胞病的新药申请，并授予其优先审评资格。该申请的PDUFA目标日期定为2026年11月1日。这一进展标志着该药物在应对这一严重血液疾病方面迈出了关键一步。
Agios Pharmaceuticals, Inc. 宣布，美国食品药品监督管理局（FDA）已接受其药物Mitapivat用于治疗镰状细胞病的新药申请，并授予其优先审评资格。该申请的PDUFA目标日期定为2026年11月1日。这一进展标志着该药物在应对这一严重血液疾病方面迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.